Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0518 versus efavirenz with Truvada in treatment-naive HIV-infected adults
2006-003109-23Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing MK-0518 + Truvada with Efavirenz + Truvada (2 arms). Primary endpoint: Proportion of patients achieving HIV RNA <50 copies/mL at Week 48. Started Sep 2006; status: completed.
02
Drugs
raltegravirefavirenzemtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-003109-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003109-23.